Henry Meiers, MD
Urology · Jeffersonville, INNPI 1245297217
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,897 of the $12,183 with a category attached, or 73.0%. Medtronic accounts for 66.1% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2023 at $3,065 and has fallen 52.4% since, to $1,459 in 2025.
Across 271 payments — averaging $44.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$8K
- Astellas Pharma US Inc$546
- Sumitomo Pharma America, Inc.$473
- Procept Biorobotics Corporation$395
- AbbVie$378
- Baxter Healthcare$317
- plus $2K from 30 others
Across 1 payment — averaging $2368.53 each. An ownership or investment interest held by the physician or an immediate family member.
- Louisville URS Solutions, LLC$2K
What the payments were for
- Speaking & faculty fees$2,00016%
- Travel & lodging$9528%
- Food & beverage$8,89773%
- Education$3343%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 129 | $8,051 |
| Astellas Pharma US Inc | 18 | $546 |
| Sumitomo Pharma America, Inc. | 17 | $473 |
| Procept Biorobotics Corporation | 7 | $395 |
| AbbVie(2 entities) | 21 | $378 |
| Baxter Healthcare | 3 | $317 |
| Urogen Pharma, Inc. | 6 | $284 |
| Merck | 5 | $160 |
| Boston Scientific | 3 | $153 |
| Teleflex LLC | 1 | $149 |
| Accord Healthcare, Inc. | 3 | $140 |
| Myriad Genetic Laboratories, Inc. | 1 | $132 |
| Blue Earth Diagnostics | 6 | $132 |
| Antares Pharma, Inc. | 7 | $98 |
| E.r. Squibb & Sons, L.L.C. | 5 | $93 |
| Axonics, Inc. | 4 | $65 |
| Myovant Sciences Inc. | 4 | $65 |
| Endo Pharmaceuticals Inc. | 3 | $54 |
| Neotract Inc. | 3 | $48 |
| Eisai Inc. | 3 | $44 |
| Verity Pharmaceuticals Inc. | 2 | $43 |
| Rochester Medical Corporation | 1 | $42 |
| Siemens Medical Solutions USA, Inc. | 1 | $39 |
| Johnson & Johnson | 3 | $34 |
| Ferring Pharmaceuticals Inc. | 2 | $32 |
| Urovant Sciences Inc | 2 | $32 |
| Calyxo, Inc. | 2 | $30 |
| Olympus America Inc. | 1 | $26 |
| Endo USA, Inc. | 1 | $25 |
| Bioprotect Medical, Inc. | 1 | $23 |
| Tolmar Pharmaceuticals, Inc. | 1 | $19 |
| Pacira Pharmaceuticals Incorporated | 1 | $15 |
| Zyla Life Sciences, Inc. | 1 | $14 |
| AstraZeneca | 1 | $13 |
| Bayer | 1 | $12 |
| Clarus Therapeutics Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,183 in reported general payments places this provider in the 80th percentile of 272 urology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 249 | $209,691 |
| GemtesaVibegron | 200 | $154,282 |
| Tamsulosin Hcl | 1,695 | $22,572 |
| Testosterone | 138 | $21,284 |
| Testosterone Cypionate | 137 | $7,271 |
| Oxybutynin Chloride ErOxybutynin Chloride | 252 | $6,533 |
| Mirabegron ErMirabegron | 13 | $4,714 |
| Finasteride | 445 | $4,416 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 201 | $3,702 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 133 | $2,811 |
| Potassium Citrate ErPotassium Citrate | 30 | $2,601 |
| Trimethoprim | 37 | $2,525 |
| Tadalafil | 17 | $2,201 |
| Cephalexin | 344 | $2,123 |
| Terazosin Hcl | 113 | $1,687 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $546 | $209,691249 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $473 | $154,282200 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 272 urology providers in Indiana.
Other urology in Jeffersonville
- James BailenJeffersonville$143K
- Greg SteinbockJeffersonville$134K
- Ryan MaloneJeffersonville$97K
- William SchmiedJeffersonville$58K
- Barry PechaJeffersonville$50K
- David RosenbaumJeffersonville$39K
- John EiflerJeffersonville$26K
- Ganesh RaoJeffersonville$19K
- Bradley BellJeffersonville$16K
- Aaron BeckerJeffersonville$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.